Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIA Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid With or Without Aspirin, for HIV-associated Tuberculous Meningitis

NCT03927313 is registered in ClinicalTrials.gov with University of Cape Town as lead sponsor.

NCT NCT03927313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03927313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIA Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid With or Without Aspirin, for HIV-associated Tuberculous Meningitis
Lead sponsor
University of Cape Town
Phase
Phase 2
Overall status
Completed
Start date
June 12, 2019
Completion date
March 31, 2021
Enrollment
52 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hiv-1-infection, tuberculosis meningitis